Medullary Thyroid Cancer: Updates and Challenges

Area of Science:

• Oncology
• Genetics
• Radiology

Background:

• Medullary thyroid cancer (MTC) management is complex, but recent advancements have improved patient outcomes.
• Germline and somatic Rearranged during transfection (RET) testing have transformed treatment strategies for MTC.
• Progress in diagnostic and therapeutic modalities has been significant over the past decade.

Purpose of the Study:

• To review recent advancements in medullary thyroid cancer diagnostics and therapeutics.
• To discuss the evolving paradigms in MTC management, focusing on RET alterations and targeted therapies.
• To highlight successes and challenges in the use of kinase inhibitors for MTC.

Main Methods:

• Review of recent literature on MTC diagnostics and treatment.
• Analysis of the impact of Germline/somatic RET testing on MTC management.
• Evaluation of novel imaging techniques and systemic therapies, including kinase inhibitors.

Main Results:

• Germline and somatic RET testing have revolutionized MTC treatment options.
• Positron emission tomography imaging and a new international grading system enhance disease characterization and prognosis.
• Selective RET kinase inhibitors like selpercatinib and pralsetinib show improved progression-free survival and tolerability.

Conclusions:

• Determining RET alteration status upfront is a key change in MTC management.
• Novel evaluation techniques and targeted therapies are improving outcomes for this rare malignancy.
• The management of medullary thyroid cancer continues to evolve with ongoing research and therapeutic development.